Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study

被引：0
|
作者：
Konstantin Huhn
Antonios Bayas
Sebastian Doerck
Benedikt Frank
Kathrin Gerbershagen
Kerstin Hellwig
Boris Kallmann
Christoph Kleinschnitz
Ingo Kleiter
De-Hyung Lee
Volker Limmroth
Mathias Mäurer
Sven Meuth
Peter Rieckmann
Tobias Ruck
Ralf Gold
Ralf A. Linker
机构：
[1] Friedrich-Alexander-University,Department of Neurology, University Hospital Erlangen
[2] Klinikum Augsburg,Department of Neurology
[3] Julius-Maximilians-University Würzburg,Department of Neurology
[4] University Hospital Essen,Department of Neurology
[5] Klinikum Köln-Merheim,Department of Neurology
[6] St. Josef-Hospital/Ruhr-University Bochum,Department of Neurology
[7] MS Center Bamberg,Department of Neurology
[8] Caritas Krankenhaus Bad Mergentheim,Department of Translational Neurology
[9] University Hospital Münster,Department of Neurology
[10] Julius-Spital Würzburg,undefined
[11] Marianne-Strauß-Klinik,undefined
[12] Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH,undefined
[13] Medical Park Klinik Loipl,undefined
来源：
Journal of Neurology | 2018年 / 265卷
关键词：
Alemtuzumab; Fingolimod; Multiple sclerosis; Disease-modifying treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1521 / 1527
页数：6
相关论文
共 50 条
  • [31] Real-World Effectiveness of Alemtuzumab in Relapsing-Remitting MS Patients in Germany: Interim Results of the TREAT-MS Study
    Akguen, Katja
    White, Robin
    Kern, Raimar
    Engelmann, Ulrich
    Haase, Rocco
    Guikema, Benjamin
    Ziemssen, Tjalf
    NEUROLOGY, 2019, 92 (15)
  • [32] Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
    Barrero, Francisco
    Mallada-Frechin, Javier
    Luisa Martinez-Gines, Maria
    Eugenia Marzo, Maria
    Meca-Lallana, Virginia
    Izquierdo, Guillermo
    Ramon Ara, Jose
    Oreja-Guevare, Celia
    Meca-Lallana, Jose
    Forero, Lucia
    Sanchez-Veram, Irene
    Jose Moreno, Maria
    PLOS ONE, 2020, 15 (04):
  • [33] Cardiac Safety of Fingolimod 0.5 mg during the First Dose Observation in 4-Month, Open-Label, Multi-Center FIRST Study in Patients with Relapsing MS
    Comi, Giancarlo
    Kappos, Ludwig
    Palace, Jacqueline
    Gottschalk, Rebecca
    Bijarnia, Mahendra
    Keil, Astrid
    Tomic, Davorka
    von Rosenstiel, Philipp
    Gold, Ralf
    NEUROLOGY, 2012, 78
  • [34] Safety of alemtuzumab in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (CARE-MS II)
    Havrdova, E.
    Arnold, D. L.
    Cohen, J.
    Coles, A. J.
    Confavreux, C.
    Fox, E. J.
    Hartung, H. -P.
    Selmaj, K.
    Weiner, H.
    Miller, T.
    Twyman, C. L.
    Lake, S. L.
    Margolin, D. H.
    Panzara, M.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 235 - 235
  • [35] Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study
    Soelberg-Sorensen, Per
    Arnold, Douglas
    Cohen, Jeffrey
    Coles, Alasdair
    Confavreux, Christian
    Fox, Edward
    Hartung, Hans
    Havrdova, Eva
    Selmaj, Krzysztof
    Weiner, Howard
    Miller, Tamara
    Twyman, Cary
    Lake, Stephen
    Margolin, David
    Richards, Susan
    Sung, Crystal
    Panzara, Michael
    Compston, Alastair
    NEUROLOGY, 2013, 80
  • [36] Incidence of Dysphagia in Patients with Fibromyalgia: A Multi-Center Cohort Study
    Chan, Shu-Yen Emily
    Ma, Kevin Sheng-Kai
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S340 - S340
  • [37] Efficacy of natalizumab in second-line therapy of relapsing remitting multiple sclerosis: results from a multi-center study in German speaking countries
    Putzki, N.
    Oezguer, Y.
    Maeurer, M.
    Cursiefen, S.
    Kuckert, S.
    Limmroth, V.
    Maschke, M.
    Tettenborn, B.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S109 - S109
  • [38] Prognosis of patients with liver cirrhosis: A multi-center retrospective observational study
    Yamana, Hayato
    Imai, Shinobu
    Yamasaki, Kazumi
    Horiguchi, Hiromasa
    Ario, Keisuke
    Komatsu, Tatsuji
    Sugimoto, Rie
    Katsushima, Shinji
    Naganuma, Atsushi
    Mano, Yutaka
    Yamashita, Tsutomu
    Kamitsukasa, Hiroshi
    Tsuruta, Satoru
    Jo, Taisuke
    Yasunaga, Hideo
    Fushimi, Kiyohide
    Yatsuhashi, Hiroshi
    HEPATOLOGY RESEARCH, 2021, 51 (12) : 1196 - 1206
  • [39] Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries
    Putzki, N.
    Yaldizli, O.
    Maeurer, M.
    Cursiefen, S.
    Kuckert, S.
    Klawe, C.
    Maschke, M.
    Tettenborn, B.
    Limmroth, V.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (01) : 31 - 37
  • [40] A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate
    Moreau, T.
    Brudon, F.
    Debouverie, M.
    Heinzlef, O.
    Lebrun-Frenay, C.
    Gury, C.
    MULTIPLE SCLEROSIS, 2006, 12 : S99 - S99
12345